CA2349217C - Cancer-associated antigens and methods of their identification - Google Patents

Cancer-associated antigens and methods of their identification Download PDF

Info

Publication number
CA2349217C
CA2349217C CA2349217A CA2349217A CA2349217C CA 2349217 C CA2349217 C CA 2349217C CA 2349217 A CA2349217 A CA 2349217A CA 2349217 A CA2349217 A CA 2349217A CA 2349217 C CA2349217 C CA 2349217C
Authority
CA
Canada
Prior art keywords
cells
tumor
prostate
incompetent
proliferation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2349217A
Other languages
English (en)
French (fr)
Other versions
CA2349217A1 (en
Inventor
Dale Ando
Ju-Fay Chang
James McArthur
Margo Roberts
Jonathon Simons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Johns Hopkins University
Biosante Pharmaceuticals Inc
Aduro Gvax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, Biosante Pharmaceuticals Inc, Aduro Gvax Inc filed Critical Johns Hopkins University
Publication of CA2349217A1 publication Critical patent/CA2349217A1/en
Application granted granted Critical
Publication of CA2349217C publication Critical patent/CA2349217C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2349217A 1998-11-03 1999-11-03 Cancer-associated antigens and methods of their identification Expired - Fee Related CA2349217C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10679598P 1998-11-03 1998-11-03
US60/106,795 1998-11-03
PCT/US1999/025936 WO2000026676A1 (en) 1998-11-03 1999-11-03 Cancer-associated antigens and methods of their identification

Publications (2)

Publication Number Publication Date
CA2349217A1 CA2349217A1 (en) 2000-05-11
CA2349217C true CA2349217C (en) 2012-07-31

Family

ID=22313292

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2349217A Expired - Fee Related CA2349217C (en) 1998-11-03 1999-11-03 Cancer-associated antigens and methods of their identification

Country Status (7)

Country Link
US (2) US7226606B2 (https=)
EP (1) EP1125133A1 (https=)
JP (1) JP2002529707A (https=)
KR (1) KR20010080384A (https=)
AU (1) AU767842B2 (https=)
CA (1) CA2349217C (https=)
WO (1) WO2000026676A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9827103D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
GB0102947D0 (en) * 2001-02-06 2001-03-21 Oxford Biomedica Ltd Method
GB2424273B (en) * 2002-11-14 2007-06-27 Univ Nottingham Method for preparing tumour marker protein
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
US20060057127A1 (en) * 2004-09-10 2006-03-16 Pocheng Liu Cytokine-expressing cellular vaccines for treatment of prostate cancer
ATE555212T1 (de) 2007-03-02 2012-05-15 Biosante Pharmaceuticals Inc Verfahren und zusammensetzungen zur identifizierung von prostatakrebs oder einer humoralen immunantwort gegen prostatakrebs
WO2008124102A2 (en) * 2007-04-06 2008-10-16 Cell Genesys Inc. Ara-c in combination with a cytokine-secreting cell and use thereof
WO2009095033A1 (en) * 2008-01-31 2009-08-06 Agirx Limited Vaccine compositons
US8840881B2 (en) 2008-08-28 2014-09-23 Aduro Gvax Inc. Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer
KR101942237B1 (ko) 2011-01-04 2019-01-25 신라젠(주) 종양 항원에 대한 항체의 생산 및 종양용해 우두 바이러스의 투여에 의한 종양 특이적 보체 의존적 세포독성의 생산
JP2016530300A (ja) * 2013-09-06 2016-09-29 ニューヨーク・ユニバーシティ シンドビスウイルスベクター及び腫瘍関連抗原を用いる抗腫瘍免疫誘導法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US4931275A (en) 1985-12-02 1990-06-05 Yeda Research & Development Co., Ltd. Anti-tumor vaccines and their preparation
US5098702A (en) 1986-04-09 1992-03-24 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US5674486A (en) 1991-06-25 1997-10-07 San Diego Regional Cancer Center Cancer immunotherapy with carrier cells
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US5904920A (en) 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US5763165A (en) 1994-03-10 1998-06-09 Ludwig Institute For Cancer Research Method for determining lung adenocarcinomas by assaying for one or more of MAGE-1, MAGE-2 and MAGE-3
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
US7176022B2 (en) 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products

Also Published As

Publication number Publication date
AU1340900A (en) 2000-05-22
JP2002529707A (ja) 2002-09-10
KR20010080384A (ko) 2001-08-22
US7226606B2 (en) 2007-06-05
AU767842B2 (en) 2003-11-27
US20060078544A1 (en) 2006-04-13
US7645587B2 (en) 2010-01-12
US20070212739A1 (en) 2007-09-13
EP1125133A1 (en) 2001-08-22
WO2000026676A1 (en) 2000-05-11
CA2349217A1 (en) 2000-05-11

Similar Documents

Publication Publication Date Title
US7645587B2 (en) Cancer-associated antigens and methods of their identification and use
Kruit et al. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE‐3 protein in patients with detectable metastatic melanoma
JP4404381B2 (ja) Ｐｓｃａ：前立腺幹細胞抗原
ES2245783T3 (es) Dominio intracelular de la proteina her-2/neu para la prevencion o el tratamiento de neoplasias malignas.
US7217421B1 (en) Cancer-associated antigens and methods of their identification and use
NZ561297A (en) Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20090074800A1 (en) Cancer antigen and use thereof
HK1202299A1 (en) Novel cancer-associated antigen
US9808516B2 (en) Immunogenic fusion proteins for the treatment of cancer
US20050221305A1 (en) Antigen panels and methods of using the same
Okada et al. Immunization with an antigen identified by cytokine tumor vaccine-assisted SEREX (CAS) suppressed growth of the rat 9L glioma in vivo
JP7216420B2 (ja) がん治療効果の検査方法及び免疫応答誘導用組成物
AU2008296927C1 (en) Methods for diagnosing and treating cancers
Bhattacharya et al. Efficacy of vaccination with plasmid DNA encoding for HER2/neu or HER2/neu-eGFP fusion protein against prostate cancer in rats
WO1999037775A2 (en) Compositions and methods for detecting and treating breast cancer
CA2643737C (en) Cancer vaccine
WO2014186596A2 (en) Correlates of efficacy relating to tumor vaccines
EP4522990B1 (en) Use of bmmf1 rep protein as diagnostic marker for pancreatic cancer and diabetes mellitus type 2
CA2416285A1 (en) Method of diagnosing, monitoring, staging, imaging and treating colon cancer
Scott Recombinant NY-ESO-1 Protein With ISCOMATRIX Adjuvant Induces Broad Integrated Antibody and CD4+ and CD8+ T Cell Responses In Humans
WO1999054466A2 (en) Colon cancer-associated antigens and their diagnostic and therapeutic uses
WO2001058947A1 (en) Lipophilin complexes for use in cancer diagnosis and therapy
WO1999037778A2 (en) Compositions and methods for detecting and treating prostate cancer

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20191104